Low-Dose Naltrexone
Sponsors
Boston Medical Center, Endeavor Health, Washington University School of Medicine, Centro Universitario La Salle, Fundació Sant Joan de Déu
Conditions
AgingAlcohol Use, UnspecifiedBladder Pain SyndromeChronic PainFibromyalgiaFrontal Fibrosing AlopeciaHIV InfectionsInterstitial Cystitis
Phase 2
St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin
CompletedNCT04052139
Start: 2021-01-25End: 2021-12-15Updated: 2022-11-10
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
CompletedNCT04409041
Start: 2019-09-01End: 2020-12-31Updated: 2021-12-30
LDN and tDCS in Fibromyalgia
CompletedNCT04502251
Start: 2018-08-01End: 2020-07-01Updated: 2020-08-06
Low-dose Naltrexone for Post-COVID Fatigue Syndrome
CompletedNCT05430152
Start: 2024-01-15End: 2026-02-28Updated: 2026-03-20
LIFT: Life Improvement Trial
RecruitingNCT06366724
Start: 2024-09-10End: 2026-11-30Target: 160Updated: 2025-10-22
Phase 4
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
TerminatedNCT04313972
Start: 2021-09-07End: 2023-02-23Updated: 2025-03-07
Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia
Active, not recruitingNCT04739995
Start: 2022-06-01End: 2024-12-31Updated: 2024-04-22